| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20051742 | HPV | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS20022496 | HPV | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44015404 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44023634 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44012773 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44041591 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44041670 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44051073 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44047171 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
| TVIS44047121 | HTLV-1 | ENSG00000140009.19 | protein_coding | ESR2 | No | No | 2100 | Q92731 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ESR2 |
|---|---|
| DrugBank ID | DB00396 |
| Drug Name | Progesterone |
| Target ID | BE0000792 |
| UniProt ID | Q92731 |
| Regulation Type | agonist |
| PubMed IDs | 20977477; 19094096; 11014241; 17341305 |
| Citations | Aguirre C, Jayaraman A, Pike C, Baudry M: Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J Neurochem. 2010 Dec;115(5):1277-87. doi: 10.1111/j.1471-4159.2010.07038.x. Epub 2010 Oct 26.@@Jayaraman A, Pike CJ: Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. J Neuroendocrinol. 2009 Jan;21(1):77-81. doi: 10.1111/j.1365-2826.2008.01801.x.@@Tessier C, Deb S, Prigent-Tessier A, Ferguson-Gottschall S, Gibori GB, Shiu RP, Gibori G: Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin. Endocrinology. 2000 Oct;141(10):3842-51. doi: 10.1210/endo.141.10.7734.@@Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22. |
| Groups | Approved; Vet_approved |
| Direct Classification | Gluco/mineralocorticoids, progestogins and derivatives |
| SMILES | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA451123 |
| ChEMBL | CHEMBL103 |
